Gilead Sciences (GILD) Share-based Compensation (2009 - 2026)

Gilead Sciences (GILD) has reported Share-based Compensation for 18 consecutive years, with $231.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation rose 2.67% year-over-year to $231.0 million; the trailing twelve-month figure through Jun 2026 stood at $909.0 million (up 4.24% YoY), and the FY2025 full-year result was $894.0 million, up 7.07% from the prior year.
• Share-based Compensation rose to $231.0 million in Q2 2026 per GILD's latest filing, from $218.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $231.0 million in Q2 2026 and bottomed at $130.0 million in Q1 2022.
• Historically, Share-based Compensation has averaged $198.9 million across 5 years, with a median of $205.5 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation dropped 6.47% in 2022, then rose 26.92% in 2023.
• Over 5 years, Share-based Compensation stood at $174.0 million in 2022, then rose by 15.52% to $201.0 million in 2023, then gained by 10.45% to $222.0 million in 2024, then gained by 3.6% to $230.0 million in 2025, then increased by 0.43% to $231.0 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $231.0 million, $218.0 million, and $230.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.